Logo

Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

Share this

Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

Shots:

  • The P-III trial involves assessing REGN-COV2 with an expected enrollment of 2000 patients at 100 sites which will be evaluated to prevent infection among uninfected people who have had close exposure to a COVID-19 patient
  • REGN-COV2 is also being evaluated in P-II/III portion of two P-I/II/III trials testing the cocktail's ability to treat hospitalized (N= 1-850) and non-hospitalized (N=1050) patients with COVID-19 across 150 sites in the US- Brazil- Mexico- and Chile with expected results in late summer. Additionally- clinical progress follows positive recommendations from IDMC of P-I trial which involved assessing of REGN-COV2 in 30 hospitalized and non-hospitalized patients with COVID-19   
  • REGN-COV2 is double-antibody cocktail developed using VelociMab and manufacturing capabilities for the prevention and treatment of COVID-19

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions